“ Independent of these efforts, however, retired pharmaceutical industry executive Alexandra Latypova made her own query into this question and later, after connecting with Paardekooper, assembled a team of researchers with experience in clinical trials, data analysis, statistics, pharmaceutical industry regulations, manufacturing, and research and development to further analyze these figures.
She produced a 20-minute video highlighting the contrast between the tremendous variability of COVID-19 gene-transfer vaccine lots as compared with seasonal flu vaccines and stressed the importance of Good Manufacturing Practice (GMP) laws that she told LifeSiteNews are “designed to ensure safety and consistency of pharmaceutical products which must be produced in large quantities to very exacting standards of purity, stability, consistency, etc.”
You must log in to post a comment.